Pfiz­er cuts eight pro­grams, in­clud­ing dwarfism drug at cen­ter of Ther­a­chon buy­out

Pfiz­er is culling a num­ber of pro­grams in its pipeline, it dis­closed in an up­date linked to its fourth quar­ter earn­ings call Tues­day.

Among those is re­cifer­cept, a drug for a form of dwarfism called achon­dropla­sia that was the cen­ter­piece of Pfiz­er’s buy­out of rare dis­ease out­fit Ther­a­chon in 2019. At the time, Pfiz­er paid $340 mil­lion up­front, with an ad­di­tion­al $470 mil­lion in mile­stones. In its earn­ings pre­sen­ta­tion, Pfiz­er said that the drug had failed a Phase II study.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER